FOLH1 and metastatic malignant neoplasm in the lymph nodes: This is in line with the findings of Hope et al., who showed that in the context of primary treatment, despite high specificity (95%), PSMA-PET has limited sensitivity (40%) for detecting very small pelvic lymph node metastases.